Unknown

Dataset Information

0

Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.


ABSTRACT: The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design.

SUBMITTER: Du Y 

PROVIDER: S-EPMC7934688 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9112270 | biostudies-literature
| S-EPMC8310126 | biostudies-literature
| S-EPMC10114927 | biostudies-literature
2023-05-01 | GSE223476 | GEO
| S-EPMC8541238 | biostudies-literature
| S-EPMC10169129 | biostudies-literature
| S-EPMC8315139 | biostudies-literature
| S-EPMC8372230 | biostudies-literature
| S-EPMC9270963 | biostudies-literature
| S-EPMC8426336 | biostudies-literature